<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560572</url>
  </required_header>
  <id_info>
    <org_study_id>Allegro</org_study_id>
    <nct_id>NCT01560572</nct_id>
  </id_info>
  <brief_title>Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen</brief_title>
  <acronym>Allegro</acronym>
  <official_title>Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open, randomized trial, in which the investigators aim to achieve optimal
      immunosuppression after renal renal transplantation with maximal reduction of side effects,
      especially of vascular injury, chronic allograft nephropathy, osteoporosis and malignancies.
      Immunosuppression without steroids and CNI minimization is compared to standard
      immunosuppression, consisting of tacrolimus OD, mycophenolic acid and corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before transplantation 300 patients will be randomized 1:1:1 in three groups. Group 1 will be
      treated with basiliximab induction and a three day course of steroids followed by a steroid
      free maintenance regimen consisting of standard-dose tacrolimus OD and mycophenolic acid.
      Group 2 will be treated with Basiliximab induction followed by standard-dose tacrolimus OD,
      mycophenolic acid and steroids. Group 3 will be treated with basiliximab induction followed
      by standard-dose tacrolimus OD for six months, whereafter the dose will be reduced plus
      mycophenolic acid and steroids. The total study period will be 2 years. Primary endpoint will
      be renal function, proteinuria and microalbuminuria measured 6, 12, and 24 months after
      transplantation. Renal function will be measured by serum Creatinine, Creatinine clearances
      and Nankivell GFR (4). Secondary endpoints will be the degree of tubular atrophy and
      interstitial fibrosis and the degree of arteriolar hyalinosis in renal biopsies taken at 12
      and 24 months after transplantation. Biopsies will be evaluated according to the Banff '07
      Criteria for Renal Allograft Biopsy Interpretation (appendix II). Quantitative morphometric
      analysis of interstitial fibrous tissue will be performed using the digital image analysis
      technique. Other secondary endpoints are patient and graft survival, the incidence of
      allograft rejection, cardiovascular accidents, pulse wave velocity, blood pressure, the
      number of antihypertensives, lipid profile, the incidence of malignancies, the incidence of
      infectious complications, the incidence of post transplant diabetes mellitus and the
      development of osteoporosis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal function parameters</measure>
    <time_frame>24 months</time_frame>
    <description>renal function as measured by serum Creatinine and Creatinine Clearance, Nankivell GFR, proteinuria and microalbuminuria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tubular atrophy and interstitial fibrosis</measure>
    <time_frame>24 months</time_frame>
    <description>tubular atrophy and interstitial fibrosis in renal biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rejection episodes</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft and patient survival</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular incidents</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infectious complications</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dexa bone densitometry</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Renal Insufficiency</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>standard immunosuupression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>steroidfree</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>maintenance immunosuppression with tacrolimus OD (target range 6-10 ng/ml), mycophenolic acid (2 dd 540 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg. After 6 months lowering of tacrolimus OD maintenance 3-5 ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus OD, mycophenolic acid, prednisolone</intervention_name>
    <description>tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group</description>
    <arm_group_label>standard immunosuupression</arm_group_label>
    <arm_group_label>steroidfree</arm_group_label>
    <arm_group_label>low dose tacrolimus</arm_group_label>
    <other_name>advagraf, mycophenolic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recipient of a kidney graft (first of second) from a deceased or living (non-HLA
             identical) donor

        Exclusion Criteria:

          -  patients with multi-organ transplants

          -  patients who are receiving a third or fourth transplant

          -  patients who have &gt; 75% (current of historic) panel reactive antibodies

          -  patients receiving a kidney from a HLA identical living donr

          -  female patients who are pregnant or unwilling to used adequate contraception during
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Stephan Sanders, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>December 31, 2014</last_update_submitted>
  <last_update_submitted_qc>December 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>J.S.F. Sanders</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>steroids</keyword>
  <keyword>tacrolimus OD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

